Goldman Sachs
LYRA

Goldman Sachs’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Goldman Sachs’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-7,404
Closed -$46.8K – 6285
2025
Q1 		$46.8K Sell
7,404
-3,706
-33% -$34.7K ﹤0.01% 5889
2024
Q4 		$115K Buy
11,110
+163
+1% +$1.79K ﹤0.01% 5741
2024
Q3 		$141K Buy
10,947
+10,459
+2,143% +$154K ﹤0.01% 5529
2024
Q2 		$6.75K Sell
488
-6,205
-93% -$701K ﹤0.01% 5558
2024
Q1 		$2.08M Buy
6,693
+6,432
+2,464% +$1.71M ﹤0.01% 3837
2023
Q4 		$68.5K Buy
+261
New +$47.2K ﹤0.01% 5346
2021
Q3 		– Sell
-215
Closed -$86K – 6394
2021
Q2 		$86K Sell
215
-4
-2% -$1.82K ﹤0.01% 5975
2021
Q1 		$127K Buy
219
+2
+0.9% +$1.25K ﹤0.01% 5774
2020
Q4 		$123K Buy
+217
New +$122K ﹤0.01% 5256
2020
Q3 		– Sell
-512
Closed -$290K – 5456
2020
Q2 		$290K Buy
+512
New +$374K ﹤0.01% 4644

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs's LYRA Position: Q2 2025 in Review

Goldman Sachs sold out of LYRA THERAPEUTICS INC (LYRA) in Q2 2025, closing a stake of 7,404 shares — an estimated $46.8K sold.

Goldman Sachs first reported a position in LYRA in Q2 2020 and held it in 10 quarters. The position peaked at $2.08M in Q1 2024. 30 funds tracked by Wall St. Rank hold LYRA as of Q2 2025.

  • Goldman Sachs reported no remaining LYRA THERAPEUTICS INC position as of Q2 2025 after selling out during the quarter.
  • Goldman Sachs sold 7,404 LYRA THERAPEUTICS INC shares in Q2 2025, an estimated $46.8K.
  • Goldman Sachs first reported a position in LYRA THERAPEUTICS INC in Q2 2020 and held it in 10 quarters.
  • Goldman Sachs's LYRA THERAPEUTICS INC position peaked at $2.08M in Q1 2024.
  • 30 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q2 2025.

Based on Goldman Sachs's 13F filing for Q2 2025, filed 14 Aug 2025.